Posted by Michael Wonder on 20 Jun 2020
FDA approves Evoke’s Gimoti
19 June 2020 - Commercial partner Eversana prepares for Gimoti launch.
Evoke Pharma today announced that the U.S. FDA has approved the new frug application for Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
